心血管转化研究的若干进展

doi:10.16138/j.1673-6087.2022.05.004

内科理论与实践 ›› 2022, Vol. 17 ›› Issue (05): 369-372.doi: 10.16138/j.1673-6087.2022.05.004

心血管转化研究的若干进展

陆林, 代杨, 王晓群, 吴立群, 张瑞岩, 沈卫峰

上海交通大学医学院附属瑞金医院心内科上海交通大学医学院心血管病研究所,上海 200025

收稿日期:2022-09-05 出版日期:2022-09-30 发布日期:2022-11-04

Several advances of translational research in cardiovascular diseases

LU Lin, DAI Yang, WANG Xiaoqun, et al

Received:2022-09-05 Online:2022-09-30 Published:2022-11-04

摘要/Abstract

关键词: 心血管疾病, 蛋白质组学, 心肌纤维化, 心房颤动, 高脂血症, 非编码RNA

中图分类号:

R587.1
R605

陆林, 代杨, 王晓群, 吴立群, 张瑞岩, 沈卫峰. 心血管转化研究的若干进展[J]. 内科理论与实践, 2022, 17(05): 369-372.

LU Lin, DAI Yang, WANG Xiaoqun, et al. Several advances of translational research in cardiovascular diseases[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 369-372.

参考文献 16

[1]	Lam MP, Ping P, Murphy E. Proteomics research in cardiovascular medicine and biomarker discovery[J]. J Am Coll Cardiol, 2016, 68(25): 2819-2830. doi: S0735-1097(16)36779-1 pmid: 28007144
[2]	Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure[J]. Heart Fail Rev, 2022, 27(2): 625-643. doi: 10.1007/s10741-021-10105-w URL
[3]	Kullo IJ, Cooper LT. Early identification of cardiovascular risk using genomics and proteomics[J]. Nat Rev Cardiol, 2010, 7(6): 309-317. doi: 10.1038/nrcardio.2010.53 pmid: 20440292
[4]	de Boer RA, De Keulenaer G, Bauersachs J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure[J]. Eur Heart J, 2019, 21(3): 272-285.
[5]	Atienza F, Martins RP, Jalife J. Translational research in atrial fibrillation[J]. Circ Arrhythm Electrophysiol, 2012, 5(6): 1207-1215. doi: 10.1161/CIRCEP.111.970335 pmid: 23022707
[6]	Nattel S, Heijman J, Zhou L, et al. Molecular basis of atrial fibrillation pathophysiology and therapy[J]. Circ Res, 2020, 127(1): 51-72. doi: 10.1161/CIRCRESAHA.120.316363 URL
[7]	Alonso R, Mata P, Muñiz O, et al. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia[J]. Atherosclerosis, 2016, 254: 249-253. doi: S0021-9150(16)31306-5 pmid: 27594539
[8]	Laugsand LE, Åsvold BO, Vatten LJ, et al. Circulating PCSK9 and risk of myocardial infarction[J]. JACC Basic Transl Sci, 2016, 1(7): 568-575. doi: 10.1016/j.jacbts.2016.06.007 pmid: 30167541
[9]	Shapiro MD, Tavori H, Fazio S. PCSK9: from basic science discoveries to clinical trials[J]. Circ Res, 2018, 122(10): 1420-1438. doi: 10.1161/CIRCRESAHA.118.311227 pmid: 29748367
[10]	Shapiro MD, Fazio S, Tavori H. Targeting PCSK9 for therapeutic gains[J]. Curr Atheroscler Rep, 2015, 17(4): 499.
[11]	Fitzgerald K, Simon A, White S, et al. A subcutaneously administered investigational RNAi therapeutic (ALN-PCSsc), targeting PCSK9 for the treatment of hypercholesterolemia: initial phase Ⅰ study results[C/OL]. http://www.pcsk9forum.org/wp-content/uploads/aln_pcssc_phase_ I_ data.pdf.
[12]	Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden[J]. Eur Heart J, 2017, 38(32): 2499-2507. doi: 10.1093/eurheartj/ehx260 pmid: 28637178
[13]	Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017, 376(18): 1713-1722. doi: 10.1056/NEJMoa1615664 URL
[14]	Poller W, Dimmeler S, Heymans S, et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives[J]. Eur Heart J, 2018, 39(29): 2704-2716. doi: 10.1093/eurheartj/ehx165 pmid: 28430919
[15]	Ravi S, Mitchell T, Kramer P, et al. Mitochondria in monocytes and macrophages-implications for translational and basic research[J]. Int J Biochem Cell Biol, 2014, 53: 202-207. doi: 10.1016/j.biocel.2014.05.019 pmid: 24863362
[16]	Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection[J]. Sci Signal, 2009, 2(100): ra81.

心血管转化研究的若干进展

Several advances of translational research in cardiovascular diseases

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 16

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴立群. 大道至简——肺静脉隔离新技术[J]. 内科理论与实践, 2022, 17(05): 357-359.
[2]	尹翔, 郑良荣. 经皮左心耳封堵预防心房颤动卒中的研究进展[J]. 内科理论与实践, 2022, 17(05): 392-395.
[3]	费镇涛, 陈牧, 李毅刚. 心房颤动导管消融后复发机制的研究进展[J]. 内科理论与实践, 2022, 17(05): 396-399.
[4]	张芝, 汤学超, 黄新苗, 秦永文. 脉冲电场消融在心房颤动中的应用[J]. 内科理论与实践, 2022, 17(05): 400-404.
[5]	徐敏, 张京岚. 非心脏手术后新发心房颤动患者的相关临床分析[J]. 内科理论与实践, 2022, 17(04): 334-336.
[6]	车在前, 赵冰, 王义辉, 朱会会, 王聿名, 祁星, 李梦娇, 陈影, 马丽, 陈尔真, 毛恩强. 胆脂复合型急性胰腺炎的临床特点分析[J]. 内科理论与实践, 2022, 17(01): 58-62.
[7]	白英, 刘心遥, 张溪林, 高兆芳, 史旭波, 邓可武. 规范抗凝对心房颤动住院患者预后的影响[J]. 内科理论与实践, 2021, 16(06): 409-412.
[8]	施仲伟. 回眸过去30年全球和中国的心血管疾病负担及其危险因素——1990年至2019年全球心血管疾病负担及其危险因素报告解读[J]. 诊断学理论与实践, 2021, 20(04): 349-355.
[9]	黄少华, 梁宗辉, 童欢, 管雪妮, 郭瑛, 张雁, 曹宾, 孙育民. 心脏磁共振评估强直性肌营养不良1型患者心肌纤维化的临床价值[J]. 诊断学理论与实践, 2021, 20(04): 362-367.
[10]	吴昊, 白英, 邓可武. 心外膜脂肪组织与心血管疾病和代谢性疾病[J]. 内科理论与实践, 2021, 16(03): 208-211.
[11]	王泽田, 吴春荣, 齐越, 徐丹, 孙科远, 唐建国. 外泌体蛋白质组学分析白念珠菌感染小鼠的标志物[J]. 外科理论与实践, 2021, 26(03): 262-268.
[12]	晏焕青, 谢琼虹, 尚达, 戴淑琪, 朱彤莹. 胎球蛋白A对腹膜透析患者冠状动脉钙化发生起始的影响因素分析[J]. 内科理论与实践, 2021, 16(01): 49-52.
[13]	刘彤, 王鑫. 心房颤动预后不良风险的评估策略[J]. 诊断学理论与实践, 2020, 19(06): 555-558.
[14]	吴歆, 耿旭强, 徐沪济. 多基因风险评分在复杂性状疾病中的应用进展[J]. 诊断学理论与实践, 2020, 19(05): 540-543.
[15]	陈鹏, 李涛. 胞外囊泡携带的非编码RNA在肝癌发生、发展中的作用[J]. 外科理论与实践, 2020, 25(05): 447-451.